

FILE 'MEDLINE' ENTERED AT 13:31:45 ON 10 FEB 2004

FILE 'CAPLUS' ENTERED AT 13:31:45 ON 10 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:31:45 ON 10 FEB 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:31:45 ON 10 FEB 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:31:45 ON 10 FEB 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 13:31:45 ON 10 FEB 2004

=> s chemotherapy
L1 571316 CHEMOTHERAPY

=> s l1 (p) (side effect)
L2 19390 L1 (P) (SIDE EFFECT)

=> s angiotensin II
L3 157551 ANGIOTENSIN II

=> s l3 (p) (analog fragment)
L4 5 L3 (P) (ANALOG FRAGMENT)

=> s l3 (p) (analog or fragment)
L5 6580 L3 (P) (ANALOG OR FRAGMENT)

=> s (hematopoietic toxicity) or (hematopoietic progenitor cell) or anemia or myelosuppression or p
5 FILES SEARCHED...

L6 529681 (HEMATOPOIETIC TOXICITY) OR (HEMATOPOIETIC PROGENITOR CELL) OR
ANEMIA OR MYELOSUPPRESSION OR PANCYTOPENIA OR THROMBOCYTOPENIA
OR NEUTROPENIA OR LYMPHOPENIA OR LEUKOPENIA OR STOMATITIS

=> s alopecia or headache or (muscle pain)
L7 188103 ALOPECIA OR HEADACHE OR (MUSCLE PAIN)

=> s l5 (p) (l6 or l7 or l2)
L8 8 L5 (P) (L6 OR L7 OR L2)

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L8
L9 8 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> d l9 1-8 ibib abs

L9 ANSWER 1 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:291697 BIOSIS
DOCUMENT NUMBER: PREV200300291697
TITLE: Methods for mobilizing hematopoietic progenitor cells from
bone marrow into peripheral blood in a patient in need of
chemotherapy.
AUTHOR(S): Rodgers, Kathleen E. [Inventor, Reprint Author]; DiZerega,
Gere [Inventor]
CORPORATE SOURCE: ASSIGNEE: University of Southern California
PATENT INFORMATION: US 6566335 May 20, 2003
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (May 20 2003) vol. 1270, No. 3.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Jun 2003
Last Updated on STN: 19 Jun 2003
AB The present invention provides improved methods, kits, and pharmaceutical
compositions for increasing white blood cell survival following
chemotherapy, and mobilizing ***hematopoietic*** ***progenitor***
cells from bone marrow into peripheral blood, comprising the
administration of an effective amount of angiotensinogen, angiotensin I

(AI), AI analogues, AI ***fragments*** and analogues thereof,
angiotensin ***II*** (AII), AII analogues, AII
fragments or analogues thereof or AII AT2 type 2 receptor
agonists.

L9 ANSWER 2 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:32036 BIOSIS
DOCUMENT NUMBER: PREV200300032036
TITLE: Methods to increase white blood cell survival after
chemotherapy.
AUTHOR(S): Rodgers, Kathleen E. [Inventor, Reprint Author]; Dizerega,
Gere [Inventor]
CORPORATE SOURCE: ASSIGNEE: University of Southern California
PATENT INFORMATION: US 6475988 November 05, 2002
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (Nov 5 2002) Vol. 1264, No. 1.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jan 2003
Last Updated on STN: 8 Jan 2003

AB The present invention provides improved methods, kits, and pharmaceutical
compositions for increasing white blood cell survival following
chemotherapy, and mobilizing ***hematopoietic*** ***progenitor***
cells from bone marrow into peripheral blood, comprising the
administration of an effective amount of angiotensinogen, angiotensin I
(AI), AI analogues, AI ***fragments*** and analogues thereof,
angiotensin ***II*** (AII), AII analogues, AII
fragments or analogues thereof or AII AT2 type 2 receptor
agonists.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:935627 CAPLUS
DOCUMENT NUMBER: 136:48819
TITLE: Methods for treating and preventing ***alopecia***
using angiotensinogen, angiotensin I,
angiotensin ***II***, their
analogs and ***fragments*** and AT2
receptor agonists
INVENTOR(S): Rodgers, Kathleen E.; Dizerega, Gere S.
PATENT ASSIGNEE(S): University of Southern California, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098325	A1	20011227	WO 2000-US32340	20001127
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1292610	A1	20030319	EP 2000-980808	20001127
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-212608P P 20000619	
			WO 2000-US32340 W 20001127	

OTHER SOURCE(S): MARPAT 136:48819

AB The present invention provides improved methods, kits, and pharmaceutical
comps. for treating and preventing ***alopecia*** in a subject in
need thereof by administering an effective amt. of angiotensinogen,
angiotensin I (AI), AI ***analogs***, AI ***fragments*** and
analogs thereof, ***angiotensin*** ***II*** (AII), AII
analogs, AII ***fragments*** or ***analogs*** thereof or
AII AT2 type 2 receptor agonists to the subject. The method further
comprises treating the subject with an effective amt. of another compd.
for treating or preventing ***alopecia***, selected from the group
consisting of minoxidol, keratinocyte growth factor, fibroblast growth

factor, epidermal growth factor, butyric acid and its derivs., ammonium trichloro(dioxyethylene-0,0') tellurate, interleukin 1, prostaglandin E2, cyclosporine A, corticosteroids and calcitriol.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2001:534172 BIOSIS
DOCUMENT NUMBER: PREV200100534172
TITLE: Method of promoting erythropoiesis.
AUTHOR(S): Rodgers, Kathleen E. [Inventor]; Dizerega, Gere [Inventor]
CORPORATE SOURCE: ASSIGNEE: University of Southern California
PATENT INFORMATION: US 6239109 May 29, 2001
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (May 29, 2001) Vol. 1246, No. 5. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Nov 2001
Last Updated on STN: 23 Feb 2002

AB The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI ***fragments*** and analogues thereof, ***angiotensin***, ***II*** analogues, AII ***fragments*** or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic ***anemia*** associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:736492 CAPLUS
DOCUMENT NUMBER: 131:347095
TITLE: Methods to increase white blood cell survival after chemotherapy using angiotensinogen, angiotensin I or II and their fragments or analogs
INVENTOR(S): Rodgers, Kathleen; Dizerega, Gere
PATENT ASSIGNEE(S): University of Southern California, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958140	A1	19991118	WO 1999-US10205	19990510
W: AU, CA, JP, MX RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2322963	AA	19991118	CA 1999-2322963	19990510
AU 9939798	A1	19991129	AU 1999-39798	19990510
AU 759285	B2	20030410		
EP 1073453	A1	20010207	EP 1999-922905	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6475988	B1	20021105	US 1999-307940	19990510
JP 2003521441	T2	20030715	JP 2000-547991	19990510
US 6566335	B1	20030520	US 2000-716394	20001120
PRIORITY APPLN. INFO.:				
			US 1998-84908P	P 19980511
			US 1998-92633P	P 19980713
			US 1999-307940	A3 19990510
			WO 1999-US10205	W 19990510

OTHER SOURCE(S): MARPAT 131:347095
AB The present invention provides improved methods, kits, and pharmaceutical comps. for increasing white blood cell survival following chemotherapy, and mobilizing ***hematopoietic*** ***progenitor*** ***cells*** from bone marrow into peripheral blood, comprising the administration of an effective amt. of angiotensinogen, angiotensin I (AI), AI ***analogs***, AI ***fragments*** and ***analogs*** thereof, ***angiotensin***, ***II*** (AII), AII ***analogs***, AII ***fragments*** or ***analogs*** thereof or AII AT2 type 2 receptor agonists.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:511174 CAPLUS
DOCUMENT NUMBER: 131:154024
TITLE: Method of promoting erythropoiesis with
angiotensinogen, angiotensins, their analogs or
fragments
INVENTOR(S): Rodgers, Kathleen E.; Dizerega, Gere
PATENT ASSIGNEE(S): University of Southern California, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940106	A2	19990812	WO 1999-US2648	19990208
WO 9940106	A3	19990923		
W: AU, CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2319701	AA	19990812	CA 1999-2319701	19990208
AU 9925916	A1	19990823	AU 1999-25916	19990208
EP 1053004	A2	20001122	EP 1999-905848	19990208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6239109	B1	20010529	US 1999-245680	19990208
JP 2002509077	T2	20020326	JP 2000-530534	19990208
PRIORITY APPLN. INFO.:				
			US 1998-74106P	P 19980209
			US 1998-111535P	P 19981209
			WO 1999-US2648	W 19990208

OTHER SOURCE(S): MARPAT 131:154024
AB The present invention provides methods, compds., pharmaceutical compns., and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI ***analogs***, AI ***fragments*** and ***analogs*** thereof, ***angiotensin***, ***II***, ***analogs***, AII ***fragments*** or ***analogs*** thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic ***anemia*** assocd. with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases. An improved cell culture medium for promotion of erythropoiesis is also claimed.

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:881400 CAPLUS
DOCUMENT NUMBER: 123:286024
TITLE: Preparation of imidazoindolizinecarboxylates and
analogues as angiotensin II antagonists
INVENTOR(S): Langlois, Pascal; Souvie, Jean-Claude; Husson, Henri-Philippe; Adam, Gerard; Renard, Pierre; Scalbert, Elizabeth
PATENT ASSIGNEE(S): Adir et Cie., Fr.
SOURCE: Fr. Demande, 34 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2712592	A1	19950524	FR 1993-13704	19931117
FR 2712592	B1	19951222		
PRIORITY APPLN. INFO.:				
			FR 1993-13704	19931117
OTHER SOURCE(S): MARPAT 123:286024				
GI				

/ Structure 1 in file .gra /

AB Title compds. [I; R1 is N-attached and = H, CH2Ph, Bz, etc.; R2,R3 = H,

alkyl, phenyl(alkyl), heterocyclyl, etc.; R4 = CH2OH, alkoxymethyl, CO2H, alkoxycarbonyl, CONH2, etc.; X = O or H2; n = 1-3] were prepd. Thus, OHCH2CH2CO2H was cyclocondensed with L-histidine to give title compd. (5S,9aR)-II. I had IC50 of <10-8M against angiotensin II binding at bovine cerebellum membrane prepn. AT2 receptors in vitro.

L9 ANSWER 8 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1981:265187 BIOSIS
DOCUMENT NUMBER: PREV198172050171; BA72:50171
TITLE: RENO VASCULAR HYPERTENSION WITH NEGATIVE RESPONSE TO ANGIOTENSIN II ANALOG TEST A CASE.
AUTHOR(S): NISHIBUCHI S [Reprint author]; KAWAMURA J; OKADA Y; YOSHIDA O; KONO T; IKEDA F
CORPORATE SOURCE: DEP UROL, FAC MED, KYOTO UNIV, KYOTO, JPN
SOURCE: Acta Urologica Japonica, (1980) Vol. 26, No. 12, pp. 1521-1528.
CODEN: HIKYAJ. ISSN: 0018-1994.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: JAPANESE

AB A case of renovascular hypertension initially diagnosed after injury was reported. The patient was a 52 yr old man who fell down from the 2nd floor and suffered from multiple bone fractures and gross hematuria. Hypotension (180/100 mmHg) and left non-visualizing kidney were found several weeks later and referred to the hospital 5 mo. after trauma with chief complaints of ***headache*** and sleeplessness. Peripheral plasma renin activity was high (3.72 ng/ml per h) and the renal vein renin ratio was 3.97 (left/right). Severe stenotic lesion of the left renal artery was shown on renal angiogram. ***Angiotensin*** ***II***
analog test did not show any decrease pattern of blood pressure as was expected, even after furosemide load. Left nephrectomy was performed and the patient became normotensive. Cases (16) were reviewed of hypertension of renal origin in which ***angiotensin*** ***II***
analog test was performed. This case was the only case of renovascular hypertension with negative response even in the state of activated renin-angiotensin-aldosterone system.

=> d his

(FILE 'HOME' ENTERED AT 13:31:24 ON 10 FEB 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:31:45 ON 10 FEB 2004

L1 571316 S CHEMOTHERAPY
L2 19390 S L1 (P) (SIDE EFFECT)
L3 157551 S ANGIOTENSIN II
L4 5 S L3 (P) (ANALOG FRAGMENT)
L5 6580 S L3 (P) (ANALOG OR FRAGMENT)
L6 529681 S (HEMATOPOIETIC TOXICITY) OR (HEMATOPOIETIC PROGENITOR CELL) O
L7 188103 S ALOPECIA OR HEADACHE OR (MUSCLE PAIN)
L8 8 S L5 (P) (L6 OR L7 OR L2)
L9 8 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> s cytokine

L10 581205 CYTOKINE

=> s (granulocyte colony stimulating factor) or (granulocyte macrophage CSF) or (epidermal growth
5 FILES SEARCHED...

L11 857346 (GRANULOCYTE COLONY STIMULATING FACTOR) OR (GRANULOCYTE MACROPHA
GE CSF) OR (EPIDERMAL GROWTH FACTOR) OR INTERLEUKIN OR THROMBOPO
IETIN

=> s (megakaryocyte development and growth factor) or (pixykines) or (stem cell factor) or (flt-li
3 FILES SEARCHED...

L12 20300 (MEGAKARYOCYTE DEVELOPMENT AND GROWTH FACTOR) OR (PIXYKINES) OR
(STEM CELL FACTOR) OR (FLT-LIGAND)

=> s l10 or l11 or l12

L13 1130437 L10 OR L11 OR L12

=> s l8 (p) l13

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L50 (P) L79'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L51 (P) L80'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'L52 (P) L81'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L53 (P) L82'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L54 (P) L83'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L55 (P) L84'
L14 1 L8 (P) L13

=> d l14 1 ibib abs

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:935627 CAPLUS
DOCUMENT NUMBER: 136:48819
TITLE: Methods for treating and preventing ***alopecia***
using angiotensinogen, angiotensin I,
angiotensin ***II***, their
analogs and ***fragments*** and AT2
receptor agonists
INVENTOR(S): Roders, Kathleen E.; Dizerega, Gere S.
PATENT ASSIGNEE(S): University of Southern California, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098325	A1	20011227	WO 2000-US32340	20001127
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1292610	A1	20030319	EP 2000-980808	20001127
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-212608P P 20000619	
			WO 2000-US32340 W 20001127	

OTHER SOURCE(S): MARPAT 136:48819

AB The present invention provides improved methods, kits, and pharmaceutical compns. for treating and preventing ***alopecia*** in a subject in need thereof by administering an effective amt. of angiotensinogen, angiotensin I (AI), AI ***analogs***, AI ***fragments*** and ***analogs*** thereof, ***angiotensin*** ***II*** (AII), AII ***analogs***, AII ***fragments*** or ***analogs*** thereof or AII AT2 type 2 receptor agonists to the subject. The method further comprises treating the subject with an effective amt. of another compd. for treating or preventing ***alopecia***, selected from the group consisting of minoxidol, keratinocyte growth factor, fibroblast growth factor, ***epidermal*** ***growth*** ***factor***, butyric acid and its derivs., ammonium trichloro(dioxyethylene-0,0') tellurate, ***interleukin*** 1, prostaglandin E2, cyclosporine A, corticosteroids and calcitriol.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> srodgers k?/au

SRODGERS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s rodgers k?/au

L15 1268 RODGERS K?/AU

=> s dizerega g?/au

L16 927 DIZEREGA G?/AU

=> s l15 or l16

L17 1904 L15 OR L16

=> d his

(FILE 'HOME' ENTERED AT 13:31:24 ON 10 FEB 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:31:45 ON 10 FEB 2004

L1 571316 S CHEMOTHERAPY
L2 19390 S L1 (P) (SIDE EFFECT)
L3 157551 S ANGIOTENSIN II
L4 5 S L3 (P) (ANALOG FRAGMENT)
L5 6580 S L3 (P) (ANALOG OR FRAGMENT)
L6 529681 S (HEMATOPOIETIC TOXICITY) OR (HEMATOPOIETIC PROGENITOR CELL) O
L7 188103 S ALOPECIA OR HEADACHE OR (MUSCLE PAIN)
L8 8 S L5 (P) (L6 OR L7 OR L2)
L9 8 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
L10 581205 S CYTOKINE
L11 857346 S (GRANULOCYTE COLONY STIMULATING FACTOR) OR (GRANULOCYTE MACRO
L12 20300 S (MEGAKARYOCYTE DEVELOPMENT AND GROWTH FACTOR) OR (PIXYKINES)
L13 1130437 S L10 OR L11 OR L12
L14 1 S L8 (P) L13
L15 1268 S RODGERS K?/AU
L16 927 S DIZEREGA G?/AU
L17 1904 S L15 OR L16

=> s l17 and l8

L18 6 L17 AND L8

=> s l18 not l8

L19 0 L18 NOT L8

=> d his

(FILE 'HOME' ENTERED AT 13:31:24 ON 10 FEB 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:31:45 ON 10 FEB 2004

L1 571316 S CHEMOTHERAPY
L2 19390 S L1 (P) (SIDE EFFECT)
L3 157551 S ANGIOTENSIN II
L4 5 S L3 (P) (ANALOG FRAGMENT)
L5 6580 S L3 (P) (ANALOG OR FRAGMENT)
L6 529681 S (HEMATOPOIETIC TOXICITY) OR (HEMATOPOIETIC PROGENITOR CELL) O
L7 188103 S ALOPECIA OR HEADACHE OR (MUSCLE PAIN)
L8 8 S L5 (P) (L6 OR L7 OR L2)
L9 8 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
L10 581205 S CYTOKINE
L11 857346 S (GRANULOCYTE COLONY STIMULATING FACTOR) OR (GRANULOCYTE MACRO
L12 20300 S (MEGAKARYOCYTE DEVELOPMENT AND GROWTH FACTOR) OR (PIXYKINES)
L13 1130437 S L10 OR L11 OR L12
L14 1 S L8 (P) L13
L15 1268 S RODGERS K?/AU
L16 927 S DIZEREGA G?/AU
L17 1904 S L15 OR L16
L18 6 S L17 AND L8
L19 0 S L18 NOT L8

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

134.48

134.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.47

-3.47

STN INTERNATIONAL LOGOFF AT 13:45:39 ON 10 FEB 2004

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	3439	chemotherapy same (side adj effect)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 12:48			0
2	BRS	L2	6547	angiotensin adj II	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 12:50			0
3	BRS	L4	43269	(hematopoietic adj toxicity) or (hematopoietic adj progenitor adj cell) or anemia or myelosuppression or pancytopenia or thrombocytopenia or neutropenia or lymphopenia or leukopenia or stomatitis or alopecia or headache or (muscle ^{adj. main})	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 12:50			0
4	BRS	L5	699	(analog or fragment) same (angiotensin adj II)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 12:51			0
5	BRS	L6	45	(1 or 4) same (2 or 5)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 12:52			0
6	BRS	L7	39386	cytokine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:14			0
7	BRS	L8	963412	(granulocyte adj colony adj stimulating adj factor) or (granulocyte adj macrophage adj csf) or (epidermal adj growth adj factor) or interleukin or thrombopoietin or (growth adj factor) or pixkines or (stem adj cell factor) or (flt adj ligand)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:18			0
8	BRS	L9	4	6 same 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:18			0
9	BRS	L11	289	(granulocyte adj macrophage adj csf)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:19			0
10	BRS	L13	4	flt-ligand	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:21			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error Count
11	BRS	L14	8	flt adj ligand	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:23			0
12	BRS	L15	2537	flt	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:23			0
13	BRS	L16	586	flt same ligand	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:23			0
14	BRS	L18	57	rodgers adj kathleen.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:27			0
15	BRS	L19	70	dizerega adj gere.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:27			0
16	BRS	L20	71	(18 or 19)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:27			0
17	BRS	L21	5	6 and 20	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 13:28			0

=> d his

(FILE 'HOME' ENTERED AT 13:31:24 ON 10 FEB 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

13:31:45 ON 10 FEB 2004

L1 571316 S CHEMOTHERAPY
L2 19390 S L1 (P) (SIDE EFFECT)
L3 157551 S ANGIOTENSIN II
L4 5 S L3 (P) (ANALOG FRAGMENT)
L5 6580 S L3 (P) (ANALOG OR FRAGMENT)
L6 529681 S (HEMATOPOIETIC TOXICITY) OR (HEMATOPOIETIC
PROGENITOR CELL) O
L7 188103 S ALOPECIA OR HEADACHE OR (MUSCLE PAIN)
L8 8 S L5 (P) (L6 OR L7 OR L2)
L9 8 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
L10 581205 S CYTOKINE
L11 857346 S (GRANULOCYTE COLONY STIMULATING FACTOR) OR
(GRANULOCYTE MACRO
L12 20300 S (MEGAKARYOCYTE DEVELOPMENT AND GROWTH FACTOR)
OR (PIXYKINES)
L13 1130437 S L10 OR L11 OR L12
L14 1 S L8 (P) L13
L15 1268 S RODGERS K?/AU
L16 927 S DIZEREGA G?/AU
L17 1904 S L15 OR L16
L18 6 S L17 AND L8
L19 0 S L18 NOT L8

=> log y

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	2	5326776.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 08:59			0
2	BRS	L2	2	5476770.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 08:59			0
3	BRS	L3	2	5624894.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 08:59			0
4	BRS	L4	2	5629292.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 08:59			0
5	BRS	L5	2	5679777.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:00			0
6	BRS	L6	2	5716935.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:00			0
7	BRS	L7	2	5824696.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:00			0
8	BRS	L8	2	5834432.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:00			0
9	BRS	L9	16	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:01			0
10	BRS	L11	14	9 and 10	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:03			0
11	BRS	L13	0	9 and 12	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:03			0
12	BRS	L12	338	(ug/kg/day)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 09:03			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	4	"6177407"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:43			0
2	BRS	L2	21	"6177407" or "6248587" or "6258778" or "6335195" or "6455500" or "6482800" or "6498138"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:44			0
3	BRS	L3	3439	chemotherapy same (side adj effect)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:44			0
4	BRS	L4	43269	(hematopoietic adj toxicity) or (hematopoietic adj progenitor adj cell) or anemia or myelosuppression or pancytopenia or thrombocytopenia or neutropenia or lymphopenia or leukopenia or stomatitis or alopecia or headache or (muscle condition)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:45			0
5	BRS	L5	338	ug/kg/day	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:45			0
6	BRS	L6	206785	effective near amount	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:47			0
7	BRS	L7	45431	3 or 4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:47			0
8	BRS	L8	206824	5 or 6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:47			0
9	BRS	L9	0	2 same 7 same 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:48			0
10	BRS	L10	107	"5326776" or "5476770" or "5451571" or "5624894" or "5629292" or "5679777" or "5716935" or "5824696" or "5834432" or "5759512"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:50			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error
11	BRS	L11	0	10 same 7 same 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/11 14:50			0